{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"spinal cord compression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"wound infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Gait disturbance"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Aphasia"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"All treatment-attributed adverse events and toxicities will be assessed, classified, and graded in accordance with the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.","groups":[{"description":"Subjects with relapsed primary central nervous system lymphoma (PCNSL) or relapsed secondary CNS lymphoma (SCNSL) without systemic disease will receive acalabrutinib until disease progression or unacceptable toxicity.","id":"OG000","title":"Open-label, Single-arm"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"up to 3 years","title":"Number of Participants With Serious Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}